Biocartis Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biocartis Group.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Medical Equipment kazanç büyümesi	19.0%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Feb 27

Recent updates

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

Jun 17

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Feb 27

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jul 28

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Biocartis Group yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

ENXTBR:BCART - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2023	61	-68	-51	-50	N/A
3/31/2023	59	-67	-49	-47	N/A
12/31/2022	58	-65	-47	-45	N/A
9/30/2022	58	-64	-53	-50	N/A
6/30/2022	59	-63	-60	-56	N/A
3/31/2022	57	-67	-64	-61	N/A
12/31/2021	55	-71	-69	-66	N/A
9/30/2021	58	-70	-60	-57	N/A
6/30/2021	61	-69	-51	-48	N/A
3/31/2021	58	-66	-47	-44	N/A
12/31/2020	56	-63	-42	-39	N/A
9/30/2020	47	-64	-47	-45	N/A
6/30/2020	38	-66	-51	-50	N/A
3/31/2020	38	-65	-54	-52	N/A
12/31/2019	38	-64	-57	-54	N/A
9/30/2019	35	-60	-56	-52	N/A
6/30/2019	33	-56	-56	-50	N/A
3/31/2019	31	-52	-52	-46	N/A
12/31/2018	29	-48	-48	-42	N/A
9/30/2018	29	-44	-46	-41	N/A
6/30/2018	29	-40	-45	-40	N/A
3/31/2018	26	-41	-45	-40	N/A
12/31/2017	23	-42	-46	-41	N/A
9/30/2017	19	-46	-51	-46	N/A
6/30/2017	14	-50	-56	-50	N/A
3/31/2017	14	-50	N/A	-52	N/A
12/31/2016	14	-50	N/A	-53	N/A
9/30/2016	14	-48	N/A	-49	N/A
6/30/2016	14	-47	N/A	-44	N/A
3/31/2016	15	-43	N/A	-36	N/A
12/31/2015	15	-40	N/A	-27	N/A
9/30/2015	15	-35	N/A	-28	N/A
6/30/2015	15	-30	N/A	-28	N/A
3/31/2015	13	-29	N/A	-32	N/A
12/31/2014	10	-29	N/A	-36	N/A
12/31/2013	12	-27	N/A	-41	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if BCART's forecast earnings growth is above the savings rate (1.3%).

Kazançlar ve Piyasa: Insufficient data to determine if BCART's earnings are forecast to grow faster than the Belgian market

Yüksek Büyüme Kazançları: Insufficient data to determine if BCART's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if BCART's revenue is forecast to grow faster than the Belgian market.

Yüksek Büyüme Geliri: Insufficient data to determine if BCART's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if BCART's Return on Equity is forecast to be high in 3 years time

Biocartis Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased to €4.75

Biocartis Group NV Provides Earnings Guidance for 2022

Price target decreased to €4.75

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

New major risk - Financial data availability

New minor risk - Financial data availability

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

New major risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Price target decreased to €6.50

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

We Think Biocartis Group (EBR:BCART) Has A Fair Chunk Of Debt

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.41

Revenue and earnings beat expectations

What Kind Of Shareholders Own Biocartis Group NV (EBR:BCART)?

What We Learned About Biocartis Group's (EBR:BCART) CEO Compensation

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Price target lowered to €7.75

New 90-day low: €4.16

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.02

What Can We Learn About Biocartis Group's (EBR:BCART) CEO Compensation?

New 90-day high - €5.01

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin